Equities analysts expect that FibroGen Inc (NASDAQ:FGEN) will report earnings per share (EPS) of ($0.49) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for FibroGen’s earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.27). FibroGen reported earnings per share of ($0.28) during the same quarter last year, which would suggest a negative year-over-year growth rate of 75%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that FibroGen will report full year earnings of ($1.09) per share for the current fiscal year, with EPS estimates ranging from ($1.63) to ($0.76). For the next year, analysts expect that the business will post earnings of ($0.32) per share, with EPS estimates ranging from ($1.75) to $1.24. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $20.44 million. During the same period in the previous year, the business earned ($0.50) earnings per share. The firm’s revenue for the quarter was down 25.1% on a year-over-year basis.
Shares of FGEN traded up $0.87 during trading hours on Tuesday, hitting $48.45. 421,464 shares of the stock were exchanged, compared to its average volume of 730,700. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16. FibroGen has a 12-month low of $33.51 and a 12-month high of $64.85. The firm has a market capitalization of $4.17 billion, a P/E ratio of -47.04 and a beta of 1.85. The stock has a 50-day moving average price of $44.73.
In other FibroGen news, Director James A. Schoeneck sold 2,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $47.02, for a total value of $94,040.00. Following the completion of the sale, the director now directly owns 5,700 shares in the company, valued at approximately $268,014. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $46.41, for a total value of $522,112.50. Following the completion of the sale, the senior vice president now owns 163,562 shares of the company’s stock, valued at $7,590,912.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 295,060 shares of company stock valued at $12,251,501. 7.83% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the business. Lindbrook Capital LLC grew its holdings in FibroGen by 150.0% in the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 300 shares in the last quarter. FTB Advisors Inc. purchased a new stake in FibroGen in the 1st quarter valued at $27,000. Manchester Capital Management LLC purchased a new stake in FibroGen in the 1st quarter valued at $39,000. Cornerstone Advisors Inc. grew its holdings in FibroGen by 672.8% in the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 693 shares in the last quarter. Finally, Quadrant Capital Group LLC purchased a new stake in FibroGen in the 1st quarter valued at $45,000. Institutional investors own 66.41% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: Why are gap-down stocks important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.